Medical center is evaluating of an Automated Physician-Directed Messaging on Patient Engagement in the Digital Diabetes Prevention Program

NYU Langone Health is recruiting patients for the clinical trial of Evaluation of an Automated Physician-Directed Messaging on Patient Engagement in the Digital Diabetes Prevention Program.

This study aims to understand the effects of automated physician directed messaging on patient engagement in the digital diabetes prevention program (dDPP). The messages are tailored to patient engagement levels based on established engagement thresholds, which are based on the patient's use of the dDPP application. The system is designed to minimize work for providers by sending automated targeted messages to patients to potentially increase engagement, prevent onset of diabetes and improve clinical outcomes. The patients in the study are automatically nudged using a combination of text messaging and MyChart messaging.

The researchers plan that February 1, 2021 will be the study start date. The indicative completion of the clinical trial will be expected in September 2022.

The study will take place at the NYU Langone Health, New York, New York, United States.

Among the inclusion conditions appear:

  • 18 years or older, BMI ≥ 25 kg/m2 (> 22 kg/m2 if self-identified as Asian).
  • A diagnosis of prediabetes (either diagnosis of prediabetes or an HbA1C level of 5.7%-6.4% in past 12 months) or diabetes risk factors (BMI ≥ 25 kg/m2 or > 22 kg/m2 if self-identified as Asian.
  • Safe to engage in moderate physical exercise (as determined by their PCP).
  • Sufficient English to be able to complete the enrollment process.
  • Has app-capable device with data to use the dDPP application and receive text messages.

The page dedicated to this clinical trial can be found here: https://ichgcp.net/clinical-trials-registry/NCT04773834

Clinical Research News

Upcoming Clinical Trials